Analysis of seven SARS-CoV-2 rapid antigen tests in detecting omicron (B.1.1.529) versus delta (B.1.617.2) using cell culture supernatants and clinical specimens.

Comparison Delta (B.1.617.2) Omicron (B.1.1.529) SARS-CoV-2 rapid antigen test Variants of concern

Journal

Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307

Informations de publication

Date de publication:
Feb 2023
Historique:
received: 26 01 2022
accepted: 27 04 2022
pubmed: 21 5 2022
medline: 31 1 2023
entrez: 20 5 2022
Statut: ppublish

Résumé

Omicron is rapidly spreading as a new SARS-CoV-2 variant of concern (VOC). The question whether this new variant has an impact on SARS-CoV-2 rapid antigen test (RAT) performance is of utmost importance. To obtain an initial estimate regarding differences of RATs in detecting omicron and delta, seven commonly used SARS-CoV-2 RATs from different manufacturers were analysed using cell culture supernatants and clinical specimens. For this purpose, cell culture-expanded omicron and delta preparations were serially diluted in Dulbecco's modified Eagle's Medium (DMEM) and the Limit of Detection (LoD) for both VOCs was determined. Additionally, clinical specimens stored in viral transport media or saline (n = 51) were investigated to complement in vitro results with cell culture supernatants. Ct values and RNA concentrations were determined via quantitative reverse transcription polymerase chain reaction (RT-qPCR). The in vitro determination of the LoD showed no obvious differences in detection of omicron and delta for the RATs examined. The LoD in this study was at a dilution level of 1:1,000 (corresponding to 3.0-5.6 × 10 In this study, RATs from various manufacturers were investigated, which displayed no obvious differences in terms of analytical LoD in vitro and RAT positivity rates based on clinical samples comparing the VOCs omicron and delta. However, differences between tests produced by various manufacturers were detected. In terms of clinical samples, a focus of this study was on specimens with high virus concentrations. Further systematic, clinical and laboratory studies utilizing large datasets are urgently needed to confirm reliable performance in terms of sensitivity and specificity for all individual RATs and SARS-CoV-2 variants.

Identifiants

pubmed: 35596057
doi: 10.1007/s15010-022-01844-5
pii: 10.1007/s15010-022-01844-5
pmc: PMC9122478
doi:

Substances chimiques

RNA 63231-63-0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

239-245

Investigateurs

Vadim Balakin (V)
Bernadett Bartha-Dima (B)
Katja Bengs (K)
Anja Berger (A)
Kerstin Boll (K)
Anja Carl (A)
Jürgen Christian (J)
Juliana Drdlicek (J)
David Eisenberger (D)
Jennifer Flechsler (J)
Lars Gerdes (L)
George Githure (G)
Janani Govindaswamy (J)
Christine Hupfer (C)
Johannes Lutmayr (J)
Gabriele Margos (G)
Roswitha Müller (R)
Silke Nickel (S)
Melanie Pavlovic (M)
Sven Pecoraro (S)
Daniel Reichwald (D)
Robert Ethan Rollins (RE)
Isabel Sahm (I)
Melanie Schauer (M)
Sandra Schmidt (S)
Gesine Schulze (G)
Anika Schülein (A)
Eva-Maria Schürmann (EM)
Nelly Scuda (N)
Judith Seebach (J)
Stefanie Singer (S)
Thorsten Stellberger (T)
Christian Tuschak (C)
Pia Zimmermann (P)

Informations de copyright

© 2022. The Author(s).

Références

Med Microbiol Immunol. 2022 Jun;211(2-3):105-117
pubmed: 35187580
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Euro Surveill. 2021 Nov;26(44):
pubmed: 34738515
Open Forum Infect Dis. 2022 Jan 28;9(3):ofac022
pubmed: 35169591
Microbiol Spectr. 2022 Aug 31;10(4):e0085322
pubmed: 35938792
J Clin Microbiol. 2022 Feb 16;60(2):e0247921
pubmed: 34936477
Microorganisms. 2021 Sep 16;9(9):
pubmed: 34576862
Anaesth Crit Care Pain Med. 2022 Feb;41(1):100998
pubmed: 34902630
Eur J Clin Microbiol Infect Dis. 2021 Jun;40(6):1303-1308
pubmed: 33512617

Auteurs

Sabrina Jungnick (S)

Public Health Microbiology Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.

Bernhard Hobmaier (B)

Public Health Microbiology Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.

Natali Paravinja (N)

Public Health Microbiology Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.

Lena Mautner (L)

Unit of Molecular Biologic Analytics and Biogenetics, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.

Mona Hoyos (M)

Unit of Molecular Biologic Analytics and Biogenetics, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.

Regina Konrad (R)

Public Health Microbiology Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.

Maren Haase (M)

Unit of Molecular Biologic Analytics and Biogenetics, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.

Armin Baiker (A)

Unit of Molecular Biologic Analytics and Biogenetics, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.

Ute Eberle (U)

Public Health Microbiology Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.

Magdalena Bichler (M)

Public Health Microbiology Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.

Bianca Treis (B)

Public Health Microbiology Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.

Mercy Okeyo (M)

Public Health Microbiology Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.

Barbara Streibl (B)

Public Health Microbiology Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.

Clara Wimmer (C)

Public Health Microbiology Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.

Sabrina Hepner (S)

Public Health Microbiology Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.

Annika Sprenger (A)

Public Health Microbiology Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.

Carola Berger (C)

Public Health Microbiology Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.

Laura Weise (L)

Public Health Microbiology Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.

Alexandra Dangel (A)

Public Health Microbiology Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.

Siegfried Ippisch (S)

Bavarian Pandemic Warehouse, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.

Walter Jonas (W)

Bavarian State Institute of Health, Oberschleißheim, Germany.

Manfred Wildner (M)

Ludwig Maximilian University, Munich, Germany.
Bavarian State Institute of Health, Oberschleißheim, Germany.

Bernhard Liebl (B)

Ludwig Maximilian University, Munich, Germany.
Bavarian State Institute of Health, Oberschleißheim, Germany.

Nikolaus Ackermann (N)

Public Health Microbiology Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.

Andreas Sing (A)

Public Health Microbiology Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.
Ludwig Maximilian University, Munich, Germany.

Volker Fingerle (V)

Public Health Microbiology Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany. volker.fingerle@lgl.bayern.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH